Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01249079|
Recruitment Status : Unknown
Verified October 2010 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : November 29, 2010
Last Update Posted : December 1, 2010
This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the National Institute of Mental Health (NIMH) Human Genetics Initiative and to apply genomic methods to further the investigators understanding of the molecular etiology of the disorder. The overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (GWAS) of the disorder. In Taiwan, there is no such kind of policy to support this kind of GWAS study as it is a very expensive study, including collecting large family samples and genome-wide single-nucleotide polymorphism (SNP) scanning. The investigators, thus, collaborate with Professor Ming T, Tsuang and his entended subcontracted researchers to apply for this project. The investigators, the research team in Taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. Through additional ascertainment within this framework, the investigators will collect an aggregate sample with adequate power for detecting in a GWAS those variants that make even small contributions to the risk for the disorder.
The investigators will meet the overarching goals of this project by accomplishing several Specific Aims, as follows: 1) Rapidly ascertain schizophrenia trio families from Taiwanese clinical ascertainment sites; 2) Supplement NIMH Genetics Initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) Assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (SNPs) and their constituent haplotypes; 4) Analyze quantitative schizophrenia phenotypes such as age at onset ; 5) Perform a genome-wide survey for copy-number variations related to schizophrenia; 6) Test for gene-gene interactions (epistasis); and 7) Test for gene-environment interactions, such as the well-established effect of season of birth.
|Condition or disease||Intervention/treatment|
|Schizophrenia||Other: No intervention would be provided in this research|
|Study Type :||Observational|
|Estimated Enrollment :||600 participants|
|Official Title:||Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan|
|Study Start Date :||October 2010|
|Estimated Primary Completion Date :||December 2013|
Other: No intervention would be provided in this research
No intervention would be provided in this research,but need to draw blood
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249079
|Contact: Hai-Gwo Hwu||886-2-23122453 ext email@example.com|
|China Medical University Hospital||Recruiting|
|Contact: Hsien-Yuan Lane|
|Study Director:||Hsien-Yuan Lane||China Medical University Hospital|